The short version of Drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
=== Cellular energy production === The conversion of ATP to ADP is the principal mechanism for energy supply in biological processes. Energy is produced in cells when the terminal phosphate group in an ATP molecule is removed from the chain to produce adenosine diphosphate (ADP) when water hydrolyzes ATP: ATP + H2O → ADP + HPO42- + H+ + energy However, removing a phosphate group from ADP to produce adenosine monophosphate (AMP) also produces extra energy.
South Africa In South Africa, the five-door-only 323 proved an immediate success. The 1.3 was gradually replaced by the larger 1.4 from July 1978, while a Special and a CS model were added at the low and high ends of the lineup respectively, complementing the existing De Luxe models. Well-equipped versions of the 1978 facelift model were sold as the "323 GLC" in South Africa. A 1600-cc model was also available in South Africa – however this model did not have a Mazda engine, unlike the rest of the range. To satisfy that country's local content regulations, a locally built Mitsubishi Saturn 1.6-litre unit was used. This produces 77 PS (57 kW) and was the most powerful engine to be installed in the FA-series Familia/323. It arrived in early 1979, but period testers felt that the less-revvy 1.6 provided very little that the 1.4 did not offer, and could not be considered to be worth the price. Fuel consumption dropped, while top speed of 148 km/h (92 mph) was only marginally higher than the 145 km/h (90 mph) of the smaller version. Sigma also fielded a rotary-engined 323 in the South African national rally championship.
Hart (1874–1953), American biochemist at the University of Wisconsin-Madison who studied farm animal diet. Brian S. Hartley FRS (1926–2021). British biochemist at Imperial College London. Known for studies on chymotrypsin and other proteolytic enzymes. Hamilton Hartridge FRS (1886–1976). British eye physiologist known in biochemistry for the continuous-flow method for following fast reactions. Demis Hassabis (b. 1976). British computer scientist and artificial intelligence researcher at University College London. Nobel Prize in chemistry 2024. Reinhart Heinrich (1946–2006). German biophysicist at the Humboldt University of Berlin, noted for the origin and development of metabolic control analysis. Max Henius (1859–1935). Danish-American biochemist who specialized in fermentation processes. Founder of the Chicago-based American Brewing Academy. Victor Henri (1872–1940). French physical chemist of Russian parents at the University of Liège. He was the first to apply ideas of physical chemistry to the properties of enzymes. Avram Hershko (b. 1937 as Herskó Ferenc). Hungarian-Israeli biochemist at the Technion (Haifa), known for the discovery of ubiquitin-mediated protein degradation. Nobel Prize in Chemistry (2004). Foreign associate Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
== Biography == Minh Le was born in Vietnam. In 1979, he and his parents left Vietnam on a boat and immigrated to Canada as refugees. Le attended Simon Fraser University from 1996 to 2001, graduating in 2001 with a Bachelor of Applied Science degree in Computing Science. His curriculum and electives were "focused mainly on computer graphics courses covering subjects such as compression algorithms, 3D animation techniques, image recognition." Le picked up id Software's Quake in 1996 and began playing with its software development kit, and after about a year he completed his first mod, Navy SEALs, Counter-Strike's spiritual predecessor. While he was working on the Action Quake 2 mod, he came up with the idea for Counter-Strike and became friends with Action Quake 2's webmaster Jess Cliffe and Marcelo Dilay. Le began work on Counter-Strike as a mod for Half-Life while he was in the middle of his fourth year at Simon Fraser University (he later graduated with a degree in computer science). He spent about 20 hours a week on making the mod, expending more effort on it than he did on his schoolwork, and released the first beta version in June 1999. The "Counter-Strike Team" quickly produced several more beta releases in the following months as the game's popularity skyrocketed. By the fourth beta version, Valve, the developer who created Half-Life, began assisting in the development of Counter-Strike. In 2000, Valve acquired the rights to Counter-Strike and hired Le and Cliffe to work at its headquarters Bellevue, Washington.
=== Necrotizing enterocolitis === Low quality evidence suggests that oral lactoferrin supplementation with or without the addition of a probiotic may decrease late onset of sepsis and necrotizing enterocolitis (stage II or III) in preterm infants with no adverse effects.
=== Cardiovascular system === Nicotine exerts several significant effects on the cardiovascular system. Primarily, it stimulates the sympathetic nervous system, leading to the release of catecholamines. This activation results in an increase in heart rate and blood pressure, as well as enhanced myocardial contractility, which raises the workload on the heart. Additionally, nicotine causes systemic vasoconstriction, including constriction of coronary arteries, which can reduce blood flow to the heart. Long-term exposure to nicotine may impair endothelial function, potentially contributing to atherosclerosis. Furthermore, nicotine has been associated with the development of cardiac arrhythmias, particularly in individuals who already have underlying heart disease. The effects of nicotine can be differentiated between short-term and long-term use. Short-term nicotine use, such as that associated with nicotine replacement therapy (NRT) for smoking cessation, appears to pose little cardiovascular risk, even for patients with known cardiovascular conditions. In contrast, longer-term nicotine use may not accelerate atherosclerosis but could contribute to acute cardiovascular events in those with pre-existing cardiovascular disease. Many severe cardiovascular effects traditionally associated with smoking may not be solely attributable to nicotine itself. Cigarette smoke contains numerous other potentially cardiotoxic substances, including carbon monoxide and oxidant gases.
Ambulatory care pharmacy (BCACP) Critical care pharmacy (BCCCP) Nuclear pharmacy (BCNP) Nutrition support pharmacy (BCNSP) Oncology pharmacy (BCOP) Pediatric pharmacy (BCPPS) Geriatric pharmacy (BCGP) Pharmacotherapy (BCPS) Infectious disease pharmacy (BCIDP) Compounded sterile preparations pharmacy (BCSCP) Cardiology pharmacy (BCCP) Emergency medicine pharmacy (BCEMP) Transplant Pharmacist (BCTXP) Psychiatric pharmacy (BCPP) There are several types of clinical pharmacists in the United States. In California they are called advanced practice pharmacists (APh). In New Mexico, they are known as Pharmacist Clinicians (PhC) and lastly in Montana and North Carolina they are known as Clinical Pharmacist Practitioners (CPP). Clinical pharmacists in the Veteran Administration are known as Clinical Pharmacy Specialists (CPS). Role in the health care system Within the system of health care, clinical pharmacists are experts in the therapeutic use of medications. They routinely provide medication therapy evaluations and recommendations to patients and other health care professionals. Clinical pharmacists are a primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications. Clinical pharmacists are also making themselves more readily available to the public. In the past, access to a clinical pharmacist was limited to hospitals, clinics, or educational institutions.
Sources: en.wikipedia.org
==== Pregnancy and breastfeeding ==== There are no adequate and well-controlled studies of the naloxone's use in pregnant women, much of the information on naloxone in pregnancy comes from studies on the use of naloxone and buprenorphine together, rather than the study of naloxone on its own. Although one study showed a possible link to preterm labor and low birth weight, but once again this study was done on women with opioid use disorder who were taking Suboxone, no studies have been done to see if treatment with naloxone for an opioid overdose can increase the chance of pregnancy-related problems. Naloxone is able to cross the placental barrier and may precipitate neonatal withdrawal, as such it is important for women taking opioids during pregnancy to inform their baby's healthcare providers so that they can check for symptoms of withdrawal, especially if they are taking medications for OUD. Small amounts of naloxone are excreted in breast milk, however, as naloxone is poorly absorbed orally it is not orally bioavailable and therefore is unlikely to affect a breastfeeding infant.
It has been found to interact with AGEs and participate in their clearance. This receptor is primarily expressed on endothelial cells and plays a role in maintaining vascular health by reducing the burden of AGE-modified proteins. SR-BII (Scavenger Receptor Class B Type II):SR-BII is similar to SR-BI but has distinct functions. It binds AGEs and has been implicated in mediating the uptake of modified proteins. SR-BII is involved in lipid transfer processes and, like SR-BI, may contribute to mitigating AGE-induced cellular stress. DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin): DC-SIGN is a receptor expressed on dendritic cells that plays a key role in pathogen recognition and immune response. Emerging research suggests that DC-SIGN can bind AGEs and mediate their clearance, reducing AGE-induced immune activation.
=== 2014 traffic collision and lawsuit === On June 7, 2014, Morgan was a passenger in a Mercedes Sprinter minibus involved in a six-vehicle crash on the New Jersey Turnpike near Cranbury when it was struck from behind by a Walmart tractor-trailer, causing a chain reaction crash. Morgan and three other comedians, including Harris Stanton, along with Morgan's assistant and two limousine company employees, who were traveling on Morgan's "Turn it Funny" stand-up comedy tour, were involved in the crash. The crash killed Morgan's friend and collaborator, 62-year-old comedian James McNair (Jimmy Mack). Morgan was taken to the hospital with a broken femur, broken nose, a traumatic brain injury, and several broken ribs, and underwent surgery on his leg on June 8. From June 20 to July 12, Morgan stayed in a rehabilitation facility to recover from the injuries sustained during the crash. The driver of the truck which caused the accident pleaded not guilty to criminal charges, and an early investigation by National Transportation Safety Board found the driver had been on the road for nearly as many hours as the legal limit. Morgan also sued Walmart for negligence, settling in 2015 for an undisclosed amount. On June 1, 2015, Morgan made his first public appearance since the crash, in an interview with Matt Lauer on Today, stating he still suffered from symptoms of his injuries. On the November 3, 2016 episode of Conan, Morgan said that he was no longer angry about the collision and had forgiven the driver.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.